MoonLake Immunotherapeutics (MLTX)

Official site

HEALTHCARE • BIOTECHNOLOGY • NASDAQ

$10.26

+0.12 (+1.18%)

Market Cap: $878.30M

Last updated: Oct 16, 2026 at 1:55 PM ET

Earnings

Performance (10Y)

Beat Rate

56%(10/18)

Avg Surprise

+1.02%

Streak

1 Q

Upcoming Estimates

Period ending Sep 30, 2026

EPS Consensus$-0.78

Range$-0.88 - $-0.66

7 analysts

EPS Revisions

30d

EPS Estimate DriftChange to current

90d ago$-0.92+15.5%

60d ago$-0.91+14.0%

30d ago$-0.780.0%

7d ago$-0.780.0%

Current$-0.78

Revenue Consensus

Range$0 - $0

12 analysts

Period ending Dec 31, 2026

EPS Consensus$-0.81

Range$-1.10 - $-0.34

7 analysts

Revenue Consensus

Range$0 - $0

13 analysts

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Dec 31, 2026Dec 26EST	-	$-0.81	$-1.10 - $-0.34	-	-	7	-	-
Sep 30, 2026Sep 26EST	-	$-0.78	$-0.88 - $-0.66	-	-	7	6 0 30d	-
Jun 30, 2026Jun 26 Reported Aug 10, 2026Reported Aug 10	$-0.84	$-0.90	$-1.02 - $-0.75	+6.67%	Beat	8	2 1 30d	+3.4%
Mar 31, 2026Mar 26 Reported May 11, 2026Reported May 11	$-0.98	$-0.92	$-1.01 - $-0.81	-6.52%	Miss	8	2 0 30d	-55.6%
Dec 31, 2025Dec 25 Reported Feb 25, 2026Reported Feb 25	$-0.92	$-0.98	$-1.03 - $-0.88	+6.05%	Beat	8	1 0 30d	-27.8%
Sep 30, 2025Sep 25 Reported Nov 5, 2025Reported Nov 5	$-1.10	$-0.89	$-0.99 - $-0.84	-23.60%	Miss	7	0 3 30d	-96.4%
Jun 30, 2025Jun 25 Reported Aug 5, 2025Reported Aug 5	$-0.87	$-0.76	$-0.83 - $-0.70	-14.47%	Miss	7	4 0 30d	-123.1%
Mar 31, 2025Mar 25 Reported May 12, 2025Reported May 12	$-0.63	$-0.74	$-0.85 - $-0.54	+14.34%	Beat	9	0 2 30d	-186.4%
Dec 31, 2024Dec 24 Reported Feb 26, 2025Reported Feb 26	$-0.72	$-0.59	$-0.76 - $-0.39	-22.03%	Miss	9	0 1 30d	-500.0%
Sep 30, 2024Sep 24 Reported Nov 7, 2024Reported Nov 7	$-0.56	$-0.45	$-0.53 - $-0.33	-24.44%	Miss	15	0 1 30d	-211.1%
Jun 30, 2024Jun 24 Reported Aug 7, 2024Reported Aug 7	$-0.39	$-0.28	$-0.38 - $-0.22	-39.29%	Miss	13	No revisions (30d)	-69.6%
Mar 31, 2024Mar 24 Reported May 7, 2024Reported May 7	$-0.22	$-0.21	$-0.30 - $-0.11	-4.76%	Miss	11	No revisions (30d)	+4.3%
Dec 31, 2023Dec 23 Reported Feb 29, 2024Reported Feb 29	$-0.12	$-0.23	$-0.37 - $-0.15	+47.83%	Beat	13	1 0 30d	+72.1%
Sep 30, 2023Sep 23 Reported Nov 14, 2023Reported Nov 14	$-0.18	$-0.25	$-0.30 - $-0.13	+28.00%	Beat	12	No revisions (30d)	+33.3%
Jun 30, 2023Jun 23 Reported Aug 10, 2023Reported Aug 10	$-0.23	$-0.29	$-0.37 - $-0.21	+20.69%	Beat	10	No revisions (30d)	+32.4%
Mar 31, 2023Mar 23 Reported May 11, 2023Reported May 11	$-0.23	$-0.31	$-0.44 - $-0.19	+25.81%	Beat	8	3 0 30d	+34.3%
Dec 31, 2022Dec 22 Reported Mar 20, 2023Reported Mar 20	$-0.43	$-0.28	$-0.38 - $-0.28	-53.57%	Miss	7	No revisions (30d)	-186.7%
Sep 30, 2022Sep 22 Reported Nov 14, 2022Reported Nov 14	$-0.27	$-0.34	$-0.37 - $-0.29	+20.59%	Beat	3	No revisions (30d)	-92.9%
Jun 30, 2022Jun 22 Reported Aug 12, 2022Reported Aug 12	$-0.34	$-0.54	$-0.55 - $-0.54	+37.04%	Beat	2	1 1 30d	-3300.0%
Mar 31, 2022Mar 22 Reported May 16, 2022Reported May 16	$-0.35	$-0.35	-	+0.00%	Beat	-	-	-3400.0%
Dec 31, 2021Dec 21 Reported Feb 17, 2022Reported Feb 17	$-0.15	N/A	-	N/A	Beat	-	-	-1400.0%
Sep 30, 2021Sep 21 Reported Nov 12, 2021Reported Nov 12	$-0.14	N/A	-	N/A	Beat	-	-	-
Jun 30, 2021Jun 21 Reported Aug 16, 2021Reported Aug 16	$-0.01	N/A	-	N/A	Beat	-	-	-
Mar 31, 2021Mar 21 Reported May 21, 2021Reported May 21	$-0.01	N/A	-	N/A	Beat	-	-	-
Dec 31, 2020Dec 20 Reported Mar 31, 2021Reported Mar 31	$-0.01	N/A	-	N/A	Beat	-	-	-
Sep 30, 2020Sep 20 Reported Dec 3, 2020Reported Dec 3	$0.00	$0.00	-	N/A	Beat	-	-	-

Key Metrics

Valuation
P/E Ratio	-2.67	EV/EBITDA	N/A
Price/FCF	N/A	FCF Yield	N/A
Profitability
Profit Margin	0.00%	Operating Margin	0.00%
ROE	-67.50%	ROIC	-48.14%
Financial Health
Debt/Equity	0.23x	Interest Coverage	-25.17x
Current Ratio	12.56x	Quick Ratio	12.56x
Trading Statistics
Beta	1.08	Avg Volume	1.96M
52-Week High	$23.29	52-Week Low	$8.80

Technical Indicators Dashboard

Moving Averages

SMA 10$10.74

SMA 20$11.45

SMA 50$13.74

SMA 200$16.63

EMA 10$10.75

EMA 20$11.44

EMA 50$13.37

EMA 200$17.82

MACD

Line: -0.99Signal: -1.02Hist: 0.03

ADX

ADX: 41.8+DI: 10.3-DI: 32.0

Aroon & PSAR

Aroon Up36.0

Aroon Down80.0

PSAR$10.78

Bollinger Bands

Upper Band$13.25

Lower Band$9.64

%B Position3153%(Upper)

Band Width0.17

RSI (14-Day)

Oversold

25.9

Momentum Oscillators

Stoch %K11.2

Stoch %D14.2

Williams %R-87.3

ROC (10d)-10.5%

Momentum-1.21

CCI (20d)-114.7

MFI (14d)30.7

Volatility Measures

ATR (14d)$0.61(6.0%)

StdDev (20d)0.90

Hist Vol44.1%(High)

Volume Flow

VWAP$10.30

OBV28.6M

AD Line-6.5M

CMF (20d)-0.174

Volume Metrics

Avg Vol (20d)1.9M

Vol Ratio0.6x

VWMA (20d)$11.44

Pivot Points

R3$11.17

R2$10.91

R1$10.53

Pivot Point$10.27

S1$9.88

S2$9.62

S3$9.23

Advanced Oscillators

TSI-47.21

Ultimate Osc35.3

KST-219.00

Financial Data

Quarter	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023
Total Revenue	$0	$0	$0	$0	$0	$0	$101,850	$0	$0	$0	$19,738	$0
Cost of Revenue	$0	$0	$751,000	$0	$0	$0	$50,925	$0	$0	$0	$3,289	$0
Gross Profit	$0	$0	$-751,000	$0	$0	$0	$50,925	$0	$0	$0	$16,449	$0

Operating Expenses	$61.66M	$70.02M	$65.22M	$71.43M	$60.70M	$47.48M	$49.58M	$43.11M	$30.58M	$19.82M	$15.03M	$12.98M
R&D	$50.22M	$54.52M	$56.01M	$60.63M	$49.76M	$36.46M	$40.36M	$35.74M	$23.66M	$13.01M	$8.10M	$7.59M
SG&A	$11.44M	$15.51M	$9.21M	$10.80M	$10.94M	$11.03M	$9.22M	$7.38M	$6.92M	$6.81M	$6.93M	$5.39M
Operating Income	$-61,660,000	$-70,024,000	$-65,217,000	$-71,434,000	$-60,698,000	$-47,485,000	$-49,581,000	$-43,112,000	$-30,578,000	$-19,820,000	$-15,028,801	$-12,976,743

Interest Income	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Interest Expense	$2.63M	$2.27M	$2.00M	$3.20M	$2.04M	$18,000	$0	$0	$0	$0	$0	$0
Income Before Tax	$-61,715,000	$-69,085,000	$-62,769,000	$-70,579,000	$-55,956,000	$-40,406,000	$-46,355,000	$-36,022,000	$-24,680,000	$-13,905,000	$-7,843,355	$-11,590,430
Income Tax Expense	$90,000	$622,000	$248,000	$115,000	$95,000	$153,000	$41,000	$92,000	$79,000	$70,000	$43,918	$28,923

Net Income	$-61,805,000	$-69,707,000	$-63,017,000	$-70,694,000	$-56,051,000	$-40,559,000	$-46,396,000	$-36,114,000	$-24,759,000	$-13,975,000	$-7,887,273	$-11,619,353

EBITDA	$-58,187,000	$-65,971,000	$-60,023,000	$-66,636,000	$-53,177,000	$-40,010,000	$-45,991,000	$-35,671,000	$-24,338,000	$-13,577,000	$-7,483,224	$-11,587,140
EBIT	$-59,083,000	$-66,816,000	$-60,774,000	$-67,381,000	$-53,919,000	$-40,388,000	$-46,355,000	$-36,022,000	$-24,680,000	$-13,905,000	$-7,843,355	$-11,590,430

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about MLTX

News

Cormorant Asset Management (MLTX) discloses 4.35% MoonLake Immunotherapeutics stake

Cormorant Asset Management, LP and Bihua Chen have disclosed a 4.35% beneficial ownership stake in MoonLake Immunotherapeutics (MLTX), totaling 3,205,433 Class A ordinary shares. This stake...

Stock Titan•Aug 14, 2026 1:40 PM ET8/14/26•Neutral

Deep Track reports 7.99M-share, 9.74% stake in MoonLake (MLTX) in 13G/A

Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have filed an amended Schedule 13G/A, reporting a collective beneficial ownership of 7,999,025 Class A ordinary shares...

Stock Titan•Aug 14, 2026 8:40 AM ET8/14/26•Neutral

MoonLake’s Psoriatic Arthritis Drug Shows Promise In Late-Stage Study

MoonLake Immunotherapeutics announced positive Week 16 topline results from its Phase 3 IZAR-1 trial for sonelokimab in biologic-naïve adults with active psoriatic arthritis...

Sahm•Aug 12, 2026 4:10 AM ET8/12/26•Somewhat-Bearish

Wall Street Analysts See a 73.35% Upside in MOONLAKE IMMUNO ( MLTX ) : Can the Stock Really Move This High?

The consensus price target hints at a 73.4% upside potential for MOONLAKE IMMUNO (MLTX). While empirical research shows that this sought-after metric is hardly effective...

Zacks Commentary•Jul 31, 2026 9:55 AM ET7/31/26•Somewhat-Bullish

MLTX Valuation and Fair Value

P/E: -2.7x
P/B: 3.5x

See GNG's fair value

MLTX Profitability: Margins, ROIC and FCF

Operating margin: 0.0%
Net margin: 0.0%
ROIC: -48.1%
ROE: -67.5%

MLTX Competitors

Company	Ticker
Theravance Biopharma Inc	TBPH
Rigel Pharmaceuticals Inc	RIGL
Beta Bionics, Inc. Common Stock	BBNX
Kura Oncology Inc	KURA
Quidel Corporation	QDEL
Si-Bone Inc	SIBN
MannKind Corp	MNKD
Jade Biosciences, Inc.	JBIO

Sector: Healthcare

MLTX Analyst Ratings

Consensus: Buy
Analysts: 15
Strong Buy: 1
Buy: 10
Hold: 2
Sell: 2
Strong Sell: 0

MLTX Bull Case vs Bear Case

Bull case

73.3% of MLTX's analyst ratings are Buy or Strong Buy.

Bear case

MLTX beat EPS estimates in 37.5% of its last 8 reported quarters.

MLTX Earnings: Beat Rate and Next Report

Beat rate: 3 of 8 quarters (37.5%)
Average surprise: -8.0%
EPS estimate (fiscal period ending Sep 30, 2026): $-0.78
Estimate revisions (30 days, fiscal period ending Sep 30, 2026): 6 up, 0 down

Frequently Asked Questions About MLTX

Does MLTX pay dividends?

MoonLake Immunotherapeutics (MLTX) does not currently pay a regular dividend.

What is MLTX's market cap?

MoonLake Immunotherapeutics (MLTX) has a market capitalization of $878.30M with a current stock price of $10.26.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In